Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Science in Sport

AIM:SIS
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SIS
AIM
£37M
Market Cap
  1. Home
  2. GB
  3. Household
Company description

Science in Sport plc, together with its subsidiaries, develops, manufactures, and markets sports nutrition products for professional athletes and sports enthusiasts. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Science in Sport has significant price volatility in the past 3 months.
SIS Share Price and Events
7 Day Returns
-8.8%
AIM:SIS
-5.4%
GB Personal Products
-5.4%
GB Market
1 Year Returns
-40.4%
AIM:SIS
-36.6%
GB Personal Products
-25.2%
GB Market
SIS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Science in Sport (SIS) -8.8% -33.3% -29.5% -40.4% -65.6% -53.4%
GB Personal Products -5.4% -28.8% -27.2% -36.6% -60.2% -32.7%
GB Market -5.4% -20.6% -29.1% -25.2% -25.9% -25.1%
1 Year Return vs Industry and Market
  • SIS underperformed the Personal Products industry which returned -36.6% over the past year.
  • SIS underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -25.2% over the past year.
Price Volatility
SIS
Industry
5yr Volatility vs Market

SIS Value

 Is Science in Sport undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Science in Sport to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Science in Sport.

AIM:SIS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.4%
Perpetual Growth Rate 10-Year GB Government Bond Rate 0.5%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AIM:SIS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 0.5%
Equity Risk Premium S&P Global 6.1%
Personal Products Unlevered Beta Simply Wall St/ S&P Global 0.6
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.597 (1 + (1- 19%) (2.92%))
0.739
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.53% + (0.8 * 6.07%)
5.39%

Discounted Cash Flow Calculation for AIM:SIS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Science in Sport is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

AIM:SIS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (GBP, Millions) Source Present Value
Discounted (@ 5.39%)
2020 -1.28 Analyst x1 -1.22
2021 2.06 Analyst x1 1.86
2022 1.66 Analyst x1 1.42
2023 1.43 Est @ -13.88% 1.16
2024 1.29 Est @ -9.56% 0.99
2025 1.21 Est @ -6.53% 0.88
2026 1.15 Est @ -4.41% 0.80
2027 1.12 Est @ -2.93% 0.74
2028 1.10 Est @ -1.89% 0.69
2029 1.09 Est @ -1.17% 0.64
Present value of next 10 years cash flows £7.00
AIM:SIS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= £1.09 × (1 + 0.53%) ÷ (5.39% – 0.53%)
£22.47
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= £22.47 ÷ (1 + 5.39%)10
£13.30
AIM:SIS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= £7.00 + £13.30
£20.30
Equity Value per Share
(GBP)
= Total value / Shares Outstanding
= £20.30 / 119.31
£0.17
AIM:SIS Discount to Share Price
Calculation Result
Value per share (GBP) From above. £0.17
Current discount Discount to share price of £0.31
= -1 x (£0.31 - £0.17) / £0.17
-82.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Science in Sport is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Science in Sport's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Science in Sport's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:SIS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in GBP £-0.05
AIM:SIS Share Price ** AIM (2020-04-03) in GBP £0.31
United Kingdom of Great Britain and Northern Ireland Personal Products Industry PE Ratio Median Figure of 5 Publicly-Listed Personal Products Companies 13.79x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 748 Publicly-Listed Companies 12.44x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Science in Sport.

AIM:SIS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:SIS Share Price ÷ EPS (both in GBP)

= 0.31 ÷ -0.05

-6.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Science in Sport is loss making, we can't compare its value to the GB Personal Products industry average.
  • Science in Sport is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Science in Sport's expected growth come at a high price?
Raw Data
AIM:SIS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Personal Products Industry PEG Ratio Median Figure of 14 Publicly-Listed Personal Products Companies 1.41x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 518 Publicly-Listed Companies 0.97x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Science in Sport, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Science in Sport's assets?
Raw Data
AIM:SIS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in GBP £0.37
AIM:SIS Share Price * AIM (2020-04-03) in GBP £0.31
United Kingdom of Great Britain and Northern Ireland Personal Products Industry PB Ratio Median Figure of 8 Publicly-Listed Personal Products Companies 0.94x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,323 Publicly-Listed Companies 1.07x
AIM:SIS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:SIS Share Price ÷ Book Value per Share (both in GBP)

= 0.31 ÷ 0.37

0.84x

* Primary Listing of Science in Sport.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Science in Sport is good value based on assets compared to the GB Personal Products industry average.
X
Value checks
We assess Science in Sport's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Science in Sport has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SIS Future Performance

 How is Science in Sport expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.4%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is Science in Sport expected to grow at an attractive rate?
  • Unable to compare Science in Sport's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Science in Sport's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Science in Sport's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:SIS Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:SIS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 16.4%
Europe Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 9.3%
United Kingdom of Great Britain and Northern Ireland Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.3%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:SIS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:SIS Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 83 1
2021-12-31 71 1
2020-12-31 60 1
2020-04-03
AIM:SIS Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-12-31 51 0 -6
2019-09-30 43 -2 -6
2019-06-30 36 -3 -6
2019-03-31 29 -5 -6
2018-12-31 21 -6 -6
2018-09-30 19 -6 -5
2018-06-30 17 -6 -4
2018-03-31 16 -4 -4
2017-12-31 16 -3 -4
2017-09-30 15 -2 -4
2017-06-30 14 -1 -4
2017-03-31 13 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Science in Sport is high growth as no earnings estimate data is available.
  • Science in Sport's revenue is expected to grow by 16.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:SIS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Science in Sport Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:SIS Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-03
AIM:SIS Past Financials Data
Date (Data in GBP Millions) EPS *
2019-12-31 -0.05
2019-09-30 -0.05
2019-06-30 -0.06
2019-03-31 -0.07
2018-12-31 -0.08
2018-09-30 -0.08
2018-06-30 -0.07
2018-03-31 -0.07
2017-12-31 -0.08
2017-09-30 -0.08
2017-06-30 -0.09
2017-03-31 -0.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Science in Sport will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Science in Sport's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Science in Sport has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SIS Past Performance

  How has Science in Sport performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Science in Sport's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Science in Sport does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Science in Sport's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Science in Sport's 1-year growth to the Europe Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Science in Sport's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Science in Sport Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:SIS Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 50.57 -5.62 23.84
2019-09-30 43.41 -5.78 22.22
2019-06-30 36.26 -5.94 20.60
2019-03-31 28.79 -5.91 18.51
2018-12-31 21.32 -5.88 16.43
2018-09-30 19.30 -5.02 15.25
2018-06-30 17.28 -4.16 14.07
2018-03-31 16.45 -3.89 13.33
2017-12-31 15.62 -3.61 12.60
2017-09-30 14.82 -3.80 12.38
2017-06-30 14.03 -4.00 12.16
2017-03-31 13.14 -3.32 10.96
2016-12-31 12.24 -2.64 9.75
2016-09-30 11.47 -1.94 8.52
2016-06-30 10.69 -1.24 7.29
2016-03-31 10.07 -1.38 7.03
2015-12-31 9.45 -1.51 6.77
2015-06-30 9.29 -2.36 7.90
2015-03-31 8.87 -1.82 7.13
2014-12-31 8.46 -1.29 6.36
2014-09-30 7.77 -1.30 6.32
2014-06-30 7.31 -1.13 5.69
2014-03-31 6.85 -0.96 4.29
2013-12-31 6.56 -0.72 4.03
2013-09-30 6.27 -0.48 3.77
2013-06-30 5.90 -0.29 3.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Science in Sport has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Science in Sport has efficiently used its assets last year compared to the GB Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Science in Sport improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Science in Sport's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Science in Sport has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SIS Health

 How is Science in Sport's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Science in Sport's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Science in Sport is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Science in Sport's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Science in Sport's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Science in Sport has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Science in Sport Company Filings, last reported 3 months ago.

AIM:SIS Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 45.20 0.00 5.37
2019-09-30 45.20 0.00 5.37
2019-06-30 47.88 0.00 5.03
2019-03-31 47.88 0.00 5.03
2018-12-31 49.82 0.00 8.00
2018-09-30 49.82 0.00 8.00
2018-06-30 20.97 0.00 10.66
2018-03-31 20.97 0.00 10.66
2017-12-31 22.81 0.00 16.57
2017-09-30 22.81 0.00 16.57
2017-06-30 9.62 0.00 3.88
2017-03-31 9.62 0.00 3.88
2016-12-31 10.82 0.00 6.13
2016-09-30 10.82 0.00 6.13
2016-06-30 11.54 0.02 6.64
2016-03-31 11.54 0.02 6.64
2015-12-31 12.02 0.05 8.75
2015-06-30 3.96 0.08 0.91
2015-03-31 3.96 0.08 0.91
2014-12-31 4.40 0.11 2.03
2014-09-30 4.61 0.13 2.33
2014-06-30 4.61 0.13 2.33
2014-03-31 2.45 0.16 0.63
2013-12-31 2.45 0.16 0.63
2013-09-30 2.99 0.19 1.40
2013-06-30 2.99 0.19 1.40
  • Science in Sport has no debt.
  • Science in Sport has no debt compared to 5 years ago when it was 2.6%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Science in Sport has sufficient cash runway for 2.2 years based on current free cash flow.
  • Unable to confirm if Science in Sport has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Science in Sport's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Science in Sport has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SIS Dividends

 What is Science in Sport's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Science in Sport dividends. Estimated to be 0% next year.
If you bought £2,000 of Science in Sport shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Science in Sport's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Science in Sport's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:SIS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.5%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 608 Stocks 5.7%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:SIS Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Science in Sport has not reported any payouts.
  • Unable to verify if Science in Sport's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Science in Sport's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Science in Sport has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Science in Sport's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.
X
Income/ dividend checks
We assess Science in Sport's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Science in Sport afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Science in Sport has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SIS Management

 What is the CEO of Science in Sport's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Moon
COMPENSATION £1,006,000
CEO Bio

Mr. Stephen N. Moon, also known as Steve, MBA serves as the Chief Executive Officer of SiS (Science in Sport) Limited. Mr. Moon served as the Chief Executive Officer of Provexis plc since July 24, 2006. Mr. Moon serves as the Managing Director at Nutrinnovator Ltd. He is responsible for identifying and implementing revenue generating opportunities, in particular pursuing key licensing agreements and was instrumental in the successful launch of Provexis Plc. He has over 25 years' senior cross-functional experience in the grocery brands industry. He worked as Strategy Planning and Worldwide Business Development Director at GlaxoSmithKline's nutritional healthcare division and in manufacturing and supply chain roles at BP, Dalgety and Quaker. He has been an Executive Director of SiS (Science in Sport) Limited since June 19, 2013. He was Non-Executive Director at Angling Direct plc from June 29, 2017 until January 23, 2019. He served as an Executive Director of Provexis plc since April 15, 2004 until December 17, 2013.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Steve Moon

TITLE
CEO & Executive Director
COMPENSATION
£1M

James Lonsdale Simpson

TITLE
CFO & Director
AGE
44
TENURE
0.6 yrs

James Morton

TITLE
Group Chief Scientific Officer
TENURE
1.2 yrs

Ashley Read

TITLE
Managing Director
Board of Directors Tenure

Average tenure and age of the Science in Sport board of directors in years:

3.6
Average Tenure
57
Average Age
  • The tenure for the Science in Sport board of directors is about average.
Board of Directors

John Clarke

TITLE
Independent Non-Executive Chairman
COMPENSATION
£119K
AGE
71
TENURE
6.8 yrs

Steve Moon

TITLE
CEO & Executive Director
COMPENSATION
£1M
TENURE
6.8 yrs

James Lonsdale Simpson

TITLE
CFO & Director
AGE
44
TENURE
0.6 yrs

Tim Wright

TITLE
Independent Non-Executive Director
COMPENSATION
£36K
AGE
60
TENURE
3.6 yrs

Roger Mather

TITLE
Independent Non-Executive Director
AGE
54
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
X
Management checks
We assess Science in Sport's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Science in Sport has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SIS News

Simply Wall St News

The Science in Sport (LON:SIS) Share Price Is Down 14% So Some Shareholders Are Getting Worried

Science in Sport plc (LON:SIS) shareholders should be happy to see the share price up 15% in the last quarter. … View our latest analysis for Science in Sport Because Science in Sport is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … In the last twelve months, Science in Sport increased its revenue by 37%.

Simply Wall St -

What Type Of Shareholder Owns Science in Sport plc's (LON:SIS)?

Science in Sport is a smaller company with a market capitalization of UK£67m, so it may still be flying under the radar of many institutional investors. … Taking a look at our data on the ownership groups (below), it's seems that institutional investors have bought into the company. … Insider Ownership Of Science in Sport While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Imagine Owning Science in Sport (LON:SIS) And Wondering If The 34% Share Price Slide Is Justified

Investors in Science in Sport plc (LON:SIS) have tasted that bitter downside in the last year, as the share price dropped 34%. … Given that Science in Sport didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … In the last twelve months, Science in Sport increased its revenue by 37%.

Simply Wall St -

Should You Worry About Science in Sport plc's (LON:SIS) CEO Pay Cheque?

How Does Steve Moon's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that Science in Sport plc has a market cap of UK£62m, and is paying total annual CEO compensation of UK£925k. … We examined a group of similar sized companies, with market capitalizations of below UK£153m

Simply Wall St -

Is Science in Sport plc's (LON:SIS) Balance Sheet Strong Enough To Weather A Storm?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

When Should You Buy Science in Sport plc (LON:SIS)?

Science in Sport plc (LON:SIS), a personal products company based in United Kingdom,. … A question to answer is whether Science in Sport's current trading price of £0.79 reflective of the actual value of the? … Let’s take a look at Science in Sport’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change

Simply Wall St -

Was Science in Sport plc's (LON:SIS) Earnings Decline Part Of A Broader Industry Downturn?

Today I will take a look at Science in Sport plc's (AIM:SIS) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the past few years, as well as how the rest of the personal products industry performed. … See our latest analysis for Science in Sport How Did SIS's Recent Performance Stack Up Against Its Past? … AIM:SIS Income Statement May 17th 18 We can further assess Science in Sport's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Is It The Right Time To Buy Science in Sport plc (LON:SIS)?

I find that Science in Sport’s ratio of 1.66x is trading slightly below its industry peers’ ratio of 2.15x, which means if you buy Science in Sport today, you’d be paying a relatively reasonable price for it. … And if you believe Science in Sport should be trading in this range, then there isn’t much room for the share price grow beyond what it’s currently trading. … Furthermore, it seems like Science in Sport’s share price is quite stable, which means there may be less chances to buy low in the future now that it’s fairly valued.

Simply Wall St -

Should You Have Science in Sport plc's (LON:SIS) In Your Portfolio?

SIS's beta implies it may be a stock that investors with high-beta portfolios might find relevant if they wanted to reduce their exposure to market risk, especially during times of downturns. … SIS, with its market capitalisation of UK£44.45M, is a small-cap stock, which generally have higher beta than similar companies of larger size. … An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Should You Buy Science in Sport plc (LON:SIS) Now?

Science in Sport plc (AIM:SIS), a personal products company based in United Kingdom, saw significant share price volatility over the past couple of months on the AIM, rising to the highs of £0.8 and falling to the lows of £0.7. … Great news for investors – Science in Sport is still trading at a fairly cheap price. … Its future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy Science in Sport.

Simply Wall St -

SIS Company Info

Description

Science in Sport plc, together with its subsidiaries, develops, manufactures, and markets sports nutrition products for professional athletes and sports enthusiasts. The company offers energy bars, gels, powders, and shots; hydration products; recovery products; protein products; supplements; and vitamins and minerals. It sells its products under the PhD Nutrition and Science in Sport brand names through e-commerce platform, third-party online and independent sports retailers, grocers, high street health chains, and international sales distributors in the United Kingdom, rest of the European Union, Australia, and internationally. Science in Sport plc was founded in 1992 and is headquartered in London, the United Kingdom.

Details
Name: Science in Sport plc
SIS
Exchange: AIM
Founded: 1992
£36,987,234
119,313,660
Website: http://www.scienceinsport.com
Address: Science in Sport plc
16-18 Hatton Garden,
4th Floor,
London,
Greater London, EC1N 8AT,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM SIS New Ordinary Shares London Stock Exchange AIM Market GB GBP 09. Aug 2013
Number of employees
Current staff
Staff numbers
142
Science in Sport employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 22:19
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/18
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.